 |
Adam Bonislawski is the editor of GenomeWeb's ProteoMonitor. He covers proteomics and life science mass spectrometry. E-mail Adam Bonislawski and follow his GenomeWeb Twitter account at @ProteoMonitor. |
Opko Inks Deal with BMS to ID Response Markers for Orencia; Again Retools Peptoid-Based Dx Platform
January 18, 2013
Opko Inks Deal with BMS to ID Response Markers for Orencia; Again Retools Peptoid-Based Dx Platform
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Opko Health Revamping Peptoid-Based Diagnostic Platform, Prepping Alzheimer's Test for Market
July 27, 2012 / ProteoMonitor - ASU's Biodesign Institute Wins $30M DoD Contract for Immunosignature-Based Pathogen Detection Chip
April 27, 2012 / ProteoMonitor - Opko Licenses Alzheimer's Diagnostic Technology to LabCorp
April 6, 2012 / ProteoMonitor - ASU Biodesign Scientists Hope to Apply Direct-to-Consumer Model to Proteomics Testing
February 4, 2011 / ProteoMonitor - Opko Partners with Bristol-Myers Squibb on Alzheimer's Blood Test
January 10, 2011 / GenomeWeb Daily News